Soligenix

About:

Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.

Website: http://soligenix.com

Twitter/X: Soligenix_Inc

Top Investors: NJEDA, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Dafna Capital Management, Biomedical Advanced Research and Development Authority (BARDA)

Description:

Soligenix is a late-stage research and development biopharmaceutical company that focuses on developing products to treat the life-threatening side effects of cancer treatment and serious gastrointestinal diseases where there remains an unmet medical need, as well as developing biodefense vaccines and therapeutics. The company maintains two business segments: BioTherapeutics and BioDefense. Its BioTherapeutics business segment focuses to develop oral beclomethasone dipropionate (orBec or oral BDP) and other biotherapeutic products, including LPMTM Leuprolide. Its BioDefense business segment focuses to convert its ricin toxin vaccine and radiation injury program from early-stage development to advanced development and manufacturing.